Booth Mark D
Chief Commercial Officer at Orexigen Therapeutics, Inc.
- Sold, on record
- $1.7M
- Dollars the filings state
- Form 4 sales
- 5
- Latest Feb 26, 2015
- Form 144 notices
- 0
- Proposed sales
- Companies
- 1
- Filed as an executive or holder
Companies
- Orexigen Therapeutics, Inc.Chief Commercial Officer
Sales by reason
Form 4 sales per month, last 12 months.
Timeline
- 1 Form 4 sale Orexigen Therapeutics, Inc.UnusualJun 28, 2012 2012
Sold 103,309 shares at $5.66 ($585k)
Booth Mark D, Chief Commercial Officer
Sold 100% of holdings ($585k position)0 shares leftFirst sale on recordFiling
- 2 Form 4 sale Orexigen Therapeutics, Inc.UnusualJan 15, 2013 +201 days
Sold 22,315 shares at $6.67 ($149k)
Booth Mark D, Chief Commercial Officer
Sold 100% of holdings ($149k position)0 shares leftFiling
- 3 Form 4 sale Orexigen Therapeutics, Inc.UnusualMar 11, 2013 +55 days
Sold 27,685 shares at $6.67 ($185k)
Booth Mark D, Chief Commercial Officer
Sold 100% of holdings ($185k position)0 shares leftFiling
- 4 Form 4 sale Orexigen Therapeutics, Inc.UnusualJul 26, 2013 +137 days
Sold 64,767 shares at $7.55 ($489k)
Booth Mark D, Chief Commercial Officer
Sold 100% of holdings ($489k position)0 shares left2.3x usual sizeFiling
- 5 Form 4 sale Orexigen Therapeutics, Inc.UnusualFeb 26, 2015 +580 days
Sold 50,000 shares at $5.68 ($284k)
Booth Mark D, Chief Commercial Officer
Sold 92.9% of holdings ($306k position)3,810 shares leftFiling
Every transaction
Loading transactions…
Sales and notices (5)
| Source | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Feb 26, 2015 | Mar 2, 2015 | Orexigen Therapeutics, Inc. | Chief Commercial Officer | Form 4 sale | 50,000 | $284k | 92.9% | Unusual | SEC |
| Jul 26, 2013 | Jul 29, 2013 | Orexigen Therapeutics, Inc. | Chief Commercial Officer | Form 4 sale | 64,767 | $489k | 100.0% | Unusual | SEC |
| Mar 11, 2013 | Mar 12, 2013 | Orexigen Therapeutics, Inc. | Chief Commercial Officer | Form 4 sale | 27,685 | $185k | 100.0% | Unusual | SEC |
| Jan 15, 2013 | Jan 18, 2013 | Orexigen Therapeutics, Inc. | Chief Commercial Officer | Form 4 sale | 22,315 | $149k | 100.0% | Unusual | SEC |
| Jun 28, 2012 | Jun 29, 2012 | Orexigen Therapeutics, Inc. | Chief Commercial Officer | Form 4 sale | 103,309 | $585k | 100.0% | Unusual | SEC |